Oritavancin - An investigational glycopeptide antibiotic

Expert Opinion on Investigational Drugs

Volumn 15, Issue 4, 2006, Pages 417-429

  Ward, Kristina E ^a   Mersfelder, Tracey L ^b   LaPlante, Kerry L ^a,b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glycopeptide; Methicillin resistant Staphylococcus aureus; Oritavancin; Vancomycin intermediate resistant Staphylococcus aureus; Vancomycin resistant Enterococcus

Indexed keywords

AMINOTRANSFERASE; AMPICILLIN; BACTERIAL PROTEIN; CEFALEXIN; CEFTRIAXONE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DEXAMETHASONE; GENTAMICIN; LINEZOLID; METICILLIN; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ACTINOMYCES; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CATHETER INFECTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DRY SKIN; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; HEADACHE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; INJECTION PAIN; INJECTION SITE REACTION; INJECTION SITE THROMBOSIS; LIPIDOSIS; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NOCARDIA; NONHUMAN; POSTANTIBIOTIC EFFECT; PROPIONIBACTERIUM; RABBIT; RAT; RHINITIS; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUGS, INVESTIGATIONAL; GLYCOPEPTIDES; HUMANS;

EID: 33645726430     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.4.417     Document Type: Article

References (90)

1. BOSSO JA: The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy (2005) 25:55S-62S.
2. TENOVER FC, McDONALD LC: Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr. Opin. Infect. Dis. (2005) 18:300-305.
3. SPELLBERG B, POWERS JH, BRASS EP, MILLER LG, EDWARDS JE Jr: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38:1279-1286.
4. ANDERSON RC, WORTH HM, HARRIS PN, CHEN KK: Vancomycin, a new antibiotic. IV. Pharmacologic and toxicologic studies. Antibiot. Ann. (1956):75-81.
5. LU W, OBERTHUR M, LEIMKUHLER C, TAO J, KAHNE D, WALSH CT: Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin. Proc. Natl. Acad. Sci. USA (2004) 101:4390-4395.
6. COOPER RD, SNYDER NJ, ZWEIFEL MJ et al.: Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot. (Tokyo) (1996) 49:575-581.
7. MALABARBA A, CIABATTI R, KETTENRING J et al: Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity. J. Antibiot. (Tokyo) (1994) 47:1493-1506.
8. ALLEN NE, NICAS TI: Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. (2003) 26:511-532.
9. MALABARBA A, NICAS TI, THOMPSON RC: Structural modifications of glycopeptide antibiotics. Med. Res. Rev. (1997) 17:69-137.
10. VAN BAMBEKE F: Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. (2004) 4:471-478.
11. SCHWALBE RS, McINTOSH AC, QAIYUMI S et al.: In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. (1996) 40:2416-2419.
12. MERCIER RC, HOULIHAN HH, RYBAK MJ: Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemotber. (1997) 41:1307-1312.
13. JONES RN, BARRETT MS, ERWIN ME: In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob. Agents Chemother. (1997) 41:488-493.
14. CANDIANI G, ABBONDI M, BORGONOVI M, ROMANO G, PARENTI F: In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. (1999) 44:179-192.
15. BIAVASCO F, VIGNAROLI C, LUPIDI R, MANSO E, FACINELLI B, VARALDO PE: In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. (1997) 41:2165-2172.
16. GARCIA-GARROTE F, CERCENADO E, ALCALA L, BOUZA E: In vitro activity of the new glycopeptide LY333328 against multiply resistant Gram-positive clinical isolates. Antimicrob. Agents Chemother. (1998) 42:2452-2455.
17. HARLAND S, TEBBS SE, ELLIOTT TS: Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J. Antimicrob. Chemother. (1998) 41:273-276.
18. JONES RN, BIEDENBACH DJ, JOHNSON DM, PFALLER MA: In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. (2001) 13:244-254.
19. PATEL R, ROUSE MS, PIPER KE, COCKERILL FR III, STECKELBERG JM: In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. (1998) 30:89-92.
20. MEZZATESTA ML, BONFIGLIO G, DE ANGELIS L, STEFANI S, RUSSO G: Study on the in-vitro activity of LY333328 against Gram-positive cocci. J. Antimicrob. Chemother. (1998) 42:266-268.
21. ZECKEL ML, PRESTON DA, ALLEN BS: In vitro activities of LY333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob. Agents Chemother. (2000) 44:1370-1374.
22. JONES RN, BARRY AL: Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. (1987) 31:625-629.
23. FASOLA E, SPANGLER SK, EDNIE LM, JACOBS MR, BAJAKSOUZIAN S, APPELBAUM PC: Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. (1996) 40:2661-2663.
24. NOVIELLO S, IANNIELLO F, ESPOSITO S: In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J. Antimicrob. Chemother. (2001) 48:283-286.
25. BOZDOGAN B, EDNIE L, CREDITO K, KOSOWSKA K, APPELBAUM PC: Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob. Agents Chemother. (2004) 48:4762-4765.
26. AESCHLIMANN JR, ALLEN GP, HERSHBERGER E, RYBAK MJ: Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. (2000) 44:2991-2998.
27. HEINE HS, DICKS R, ANDREWS G: In vitro activity of oritavancin (LY333328), levofloxacin, meropenem, GAR 936 and linezolid against strains of Bacillus anthracis. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2001):173.
28. ARTHUR M, REYNOLDS P, COURVALIN P: Glycopeptide resistance in enterococci. Trends Microbiol. (1996) 4:401-407.
29. PERICHON B, REYNOLDS P, COURVALIN P: VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob. Agents Chemother. (1997) 41:2016-2018.
30. BOZDOGAN B, ESEL D, WHITENER C, BROWNE FA, APPELBAUM PC: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52:864-868.
31. SILLERSTROM E, WAHLUND E, NORD CE: In vitro activity of LY 333328 against anaerobic Gram-positive bacteria. J. Chemother. (1999) 11:90-92.
32. ARTHUR M, DEPARDIEU F, REYNOLDS P, COURVALIN P: Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob. Agents Chemother. (1999) 43:1875-1880.
33. LARSSON AJ, WALKER KJ, RADDATZ JK, ROTSCHAFER JC: The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J. Antimicrob. Chemother. (1996) 38:589-597.
34. LOWDIN E, ODENHOLT I, CARS O: In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. (1998) 42:2739-2744.
35. HARDING I, MacGOWAN AP, WHITE LO, DARLEY ES, REED V: Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J. Antimicrob. Chemother. (2000) 45:835-841.
36. BOYLAN CJ, CAMPANALE K, IVERSEN PW, PHILLIPS DL, ZECKEL ML, PARR TR Jr: Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. (2003) 47:1700-1706.
37. LIN G, CREDITO K, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. (2005) 49:770-772.
38. SARIBAS S, BAGDATLI Y: Vancomycin tolerance in enterococci. Chemotherapy (2004) 50:250-254.
39. GILLIS LM, WHITE HD, WHITEHURST A, SULLIVAN DC: Vancomycin-tolerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999-2001. Am. J. Med. Sci. (2005) 330:65-68.
40. SAKOULAS G, ELIOPOULOS GM, MOELLERING RC Jr et al: Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. (2002) 46:1492-1502.
41. MacKENZIE FM, GOULD IM: The post-antibiotic effect. J. Antimicrob. Chemother. (1993) 32:519-537.
42. BALTCH AL, SMITH RP, RITZ WJ, BOPP LH: Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. (1998) 42:2564-2568.
43. LEFORT A, SALEH-MGHIR A, GARRY L, CARBON C, FANTIN B: Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob. Agents Chemother. (2000) 44:3017-3021.
44. BHAVNANI SM, OWEN JS, LOUTIT JS, PORTER SB, AMBROSE PG: Pharmacokinetics, safety; and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn. Microbiol. Infect. Dis. (2004) 50:95-102.
45. FETTERLY GJ, ONG CM, BHAVNANI SM et al: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob. Agents Chemother. (2005) 49:148-152.
46. RODVOLD KA, GOTFRIED MH, LOUTIT JS, PORTER SB: Plasma and interpulmonary concentrations of oritavancin and vancomycin in normal healthy adults. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic (1 - 4 May 2004).
47. 14C-oritavancin. The 41st Interscience Conference on Antimicrobial and Chemotherapy, Washington, DC, USA (16 - 19 December 2001).
48. Vancocin HCl (vancomycin injection, USP). Baxter Healthcare Corporation, Deerfield, USA (2003) (package insert).
49. BABUL N, PASKO M: Teicoplanin: a new glycopeptide antibiotic complex. Drug Intell. Clin. Pharm. (1988) 22:218-226.
50. VAN BAMBEKE F, CARRYN S, SERAL C et al.: Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. (2004) 48:2853-2860.
51. LAMER C, DE BECO V, SOLER P et al.: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. (1993) 37:281-286.
52. OWEN JS, BHAVNANI SM, FIELDER-KELLY J, LOUTIT JS, PORTER SB: Population pharmacokinetics of oritavancin. 44th International Conference on Antimicrobial Agents of Chemotherapy, Washington, DC, USA (2004):A-20.
53. WASILEWSKI M, DISCH D, McGILL J, HARRIS H, O'RIORDAN W, ZECKEL ML: Equivalence of shorter course therapy with oritavancin versus vancomycin/ cephalexin in complicated skin/skin structure infections (CSSI). The 41st Interscience Conference on Antimicrobial and Chemotherapy Washington, DC, USA (16 - 19 December 2001).
54. GIAMARELLOU H, O'RIORDAN W, HARRIS H, OWEN S, PORTER S, LOUTIT J: Phase III trial comparing 3 - 7 days of oritavancin versus 10 - 14 days of vancomycin/cephalexin in the treatment of patients with complicated skin/ skin structure infections (CSSI). The 41st Interscience Conference on Antimicrobial and Chemotherapy, Washington, DC, USA (16 - 19 December 2001).
55. VAN BAMBEKE F, SAFFRAN J, MINGEOT-LECLERCQ MP, TULKENS PM: Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob. Agents Chemother. (2005) 49:1695-1700.
56. TABAS I: Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J. Clin. Invest. (2002) 110:905-911.
57. REASOR MJ, KACEW S: Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. (Maywood) (2001) 226:825-830.
58. MULLER-HOCKER J, SCHMID H, WEISS M, DENDORFER U, BRAUN GS: Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. Hum. Pathol. (2003) 34:285-289.
59. MUNOZ SJ, MARTINEZ-HERNANDEZ A, MADDREY WC: Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim - sulfamethoxazole. Hepatology (1990) 12:342-347.
60. RUPP ME, FEY PD, LONGO GM: Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J. Antimicrob. Chemother. (2001) 47:705-707.
61. GERBER J, SMIRNOV A, WELLMER A et al.: Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob. Agents Chemother. (2001) 45:2169-2172.
62. CABELLOS C, FERNANDEZ A, MAIQUES JM et al.: Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. (2003) 47:1907-1911.
63. KAATZ GW, SEO SM, AESCHLIMANN JR, HOULIHAN HH, MERCIER RC, RYBAK MJ: Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. (1998) 42:981-983.
64. SALEH-MGHIR A, LEFORT A, PETEGNIEF Y et al.: Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. (1999) 43:115-120.
65. TORRES-VIERA C, DEMBRY LM: Approaches to vancomycin-resistant enterococci. Curr. Opin. Infect. Dis. (2004) 17:541-547.
66. BURLESON BS, RITCHIE DJ, MICEK ST, DUNNE WM: Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy (2004) 24:1225-1231.
67. MUNOZ-PRICE LS, LOLANS K, QUINN JP: Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin. Infect. Dis. (2005) 41:565-566.
68. BASSETTI M, FARREL PA, CALLAN DA, TOPAL JE, DEMBRY LM: Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int. J. Antimicrob. Agents (2003) 21:593-594.
69. ROSE CM, REILLY KJ, HAITH LR et al.: Emergence of resistance of vancomycin-resistant Enterococcus faecium in a thermal injury patient treated with quinupristin - dalfopristin and cultured epithelial autografts for wound closure. Burns (2002) 28:696-698.
70. BARRY AL, FUCHS PC, BROWN SD: In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. (2001) 45:1919-1922.
71. RYBAK MJ, HERSHBERGER E, MOLDOVAN T, GRUCZ RG: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. (2000) 44:1062-1066.
72. KING A, PHILLIPS I: The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J. Antimicrob. Chemother. (2001) 48:219-223.
73. CRITCHLEY IA, DRAGHI DC, SAHM DF, THORNSBERRY C, JONES ME, KARLOWSKY JA: Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J. Antimicrob. Chemother. (2003) 51:639-649.
74. SNYDMAN DR, JACOBUS NV, McDERMOTT LA, LONKS JR, BOYCE JM: Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2000) 44:3447-3450.
75. ZURENKO GE, YAGI BH, SCHAADT RD et al: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. (1996) 40:839-845.
76. JONES RN, JOHNSON DM, ERWIN ME: In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. (1996) 40:720-726.
77. BRICKNER SJ, HUTCHINSON DK, BARBACHYN MR et al.: Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. (1996) 39:673-679.
78. FORD CW, HAMEL JC, WILSON DM et al.: In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob. Agents Chemother (1996) 40:1508-1513.
79. ELIOPOULOS GM, WENNERSTEN CB, GOLD HS, MOELLERING RC Jr: In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob. Agents Chemother. (1996) 40:1745-1747.
80. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51:902.
81. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51:565-567.
82. PETERSEN PJ, BRADFORD PA, WEISS WJ, MURPHY TM, SUM PE, PROJAN SJ: In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46:2595-2601.
83. RYBAK MJ, CAPPELLETTY DM, MOLDOVAN T, AESCHLIMANN JR, KAATZ GW: Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents Chemother. (1998) 42:721-724.
84. BAYES M, RABASSEDA X, PROUS JR: Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol. (2002) 24:159-184.
85. FASS RJ, HELSEL VL: In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. (1986) 30:781-784.
86. FUCHS PC, BARRY AL, BROWN SD: In vitro bactericidal activity of daptomycin against staphylococci. Antimicrob. Agents Chemother. (2002) 49:467-470.
87. ZHANEL GG, PALATNICK L, NICHOL KA, BELLYOU T, LOW DE, HOBAN DJ: Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. (2003) 47:1867-1874.
88. GOLDSTEIN EJ, CITRON DM, MERRIAM CV, WARREN Y, TYRRELL K, FERNANDEZ HT: In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antinticrob. Agents Chemother. (2003) 47:1968-1971.
89. GOLDSTEIN EJ, CITRON DM, MERRIAM CV, WARREN YA, TYRRELL KL, FERNANDEZ HT: In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 Gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob. Agents Chemother. (2003) 47:337-341.
90. CHIEN J, ALLERHEILIGEN S, PHILLIPS DL, CERIMELE B, THOMASSON HR: Safety and pharmacokinetics of single intravenous doses of LY333328 diphosphate (glycopeptide) in healthy men. 38th ICAAC, San Diego, USA (1998):A-55.